FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892754564> ?p ?o ?g. }

• W2892754564 endingPage "185" @default.
• W2892754564 startingPage "176" @default.
• W2892754564 abstract "Phosphodiesterase 2 (PDE2) plays an important role in treatment of stress-related depression through regulation of antioxidant defense and neuroprotective mechanisms. However, the causal relationship between PDE2 and the prevalence of depression and anxiety upon exposure to oxidative stress has not been investigated. The present study examined whether the effects of PDE2 inhibition on oxidative stress were directly involved in reduced ROS by regulating NADPH subunits gp91phox oxidase. The results suggested that the PDE2 inhibitor Bay 60-7550 reversed oxidative stress-induced behavioral signature, i.e. depression and anxiety. Pretreatment with the oxidizing agent DTNB completely blocked, while the reducing agent DTT and the NADPH oxidase inhibitor apocynin potentiated the effects of Bay 60-7550 on behavioral abnormalities, demonstrating the relationship between PDE2 and oxidative stress. Consistently, an in vitro test revealed the positive correlation between ROS and PDE2 levels. Moreover, Bay 60-7550 decreased corticosterone-induced gp91phox expression, which is the source of ROS. The subsequent study suggested that Bay 60-7550 induced decrease in ROS and increase in cAMP/cGMP, pVASP, pCREB, and the neurotrophic factor BDNF levels, which were completely blocked by CRISPR/Cas9-mediated gp91phox overexpression and potentiated by gp91phox siRNA-based antioxidant strategies. The in vivo test in stressed mice further suggested that gp91phox overexpression completely blocked the antidepressant- and anxiolytic-like effects of Bay 60-7550, while gp91phox knockdown enhanced such effects. These results provide solid evidence that the antidepressant- and anxiolytic-like effects of Bay 60-7550 against stress are causally related to down-regulation of gp91phox and activation of the cAMP/cGMP-pVASP-CREB-BDNF signaling pathway." @default.
• W2892754564 created "2018-10-05" @default.
• W2892754564 creator A5005260055 @default.
• W2892754564 creator A5009094213 @default.
• W2892754564 creator A5014975276 @default.
• W2892754564 creator A5026561351 @default.
• W2892754564 creator A5028541832 @default.
• W2892754564 creator A5030280915 @default.
• W2892754564 creator A5032535647 @default.
• W2892754564 creator A5044104772 @default.
• W2892754564 creator A5053505858 @default.
• W2892754564 creator A5071772212 @default.
• W2892754564 creator A5075430732 @default.
• W2892754564 creator A5091864839 @default.
• W2892754564 date "2018-12-01" @default.
• W2892754564 modified "2023-09-25" @default.
• W2892754564 title "Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression- and anxiety-like behavior" @default.
• W2892754564 cites W1526841021 @default.
• W2892754564 cites W1647222892 @default.
• W2892754564 cites W1841473218 @default.
• W2892754564 cites W1975906565 @default.
• W2892754564 cites W1991605631 @default.
• W2892754564 cites W1994996694 @default.
• W2892754564 cites W2009565960 @default.
• W2892754564 cites W2016883839 @default.
• W2892754564 cites W2017749659 @default.
• W2892754564 cites W2020788145 @default.
• W2892754564 cites W2031193867 @default.
• W2892754564 cites W2035384082 @default.
• W2892754564 cites W2037039729 @default.
• W2892754564 cites W2041068600 @default.
• W2892754564 cites W2049947409 @default.
• W2892754564 cites W2085128107 @default.
• W2892754564 cites W2088866343 @default.
• W2892754564 cites W2094056330 @default.
• W2892754564 cites W2096951505 @default.
• W2892754564 cites W2098282522 @default.
• W2892754564 cites W2117445070 @default.
• W2892754564 cites W2121559132 @default.
• W2892754564 cites W2124646812 @default.
• W2892754564 cites W2145989836 @default.
• W2892754564 cites W2157332070 @default.
• W2892754564 cites W2162572715 @default.
• W2892754564 cites W2193839494 @default.
• W2892754564 cites W2211143979 @default.
• W2892754564 cites W2583487413 @default.
• W2892754564 doi "https://doi.org/10.1016/j.neuropharm.2018.09.039" @default.
• W2892754564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268520" @default.
• W2892754564 hasPublicationYear "2018" @default.
• W2892754564 type Work @default.
• W2892754564 sameAs 2892754564 @default.
• W2892754564 citedByCount "17" @default.
• W2892754564 countsByYear W28927545642020 @default.
• W2892754564 countsByYear W28927545642021 @default.
• W2892754564 countsByYear W28927545642022 @default.
• W2892754564 countsByYear W28927545642023 @default.
• W2892754564 crossrefType "journal-article" @default.
• W2892754564 hasAuthorship W2892754564A5005260055 @default.
• W2892754564 hasAuthorship W2892754564A5009094213 @default.
• W2892754564 hasAuthorship W2892754564A5014975276 @default.
• W2892754564 hasAuthorship W2892754564A5026561351 @default.
• W2892754564 hasAuthorship W2892754564A5028541832 @default.
• W2892754564 hasAuthorship W2892754564A5030280915 @default.
• W2892754564 hasAuthorship W2892754564A5032535647 @default.
• W2892754564 hasAuthorship W2892754564A5044104772 @default.
• W2892754564 hasAuthorship W2892754564A5053505858 @default.
• W2892754564 hasAuthorship W2892754564A5071772212 @default.
• W2892754564 hasAuthorship W2892754564A5075430732 @default.
• W2892754564 hasAuthorship W2892754564A5091864839 @default.
• W2892754564 hasConcept C134018914 @default.
• W2892754564 hasConcept C170493617 @default.
• W2892754564 hasConcept C185592680 @default.
• W2892754564 hasConcept C2776151105 @default.
• W2892754564 hasConcept C2777209548 @default.
• W2892754564 hasConcept C2777765862 @default.
• W2892754564 hasConcept C2778004101 @default.
• W2892754564 hasConcept C2778979269 @default.
• W2892754564 hasConcept C2779177272 @default.
• W2892754564 hasConcept C2779719074 @default.
• W2892754564 hasConcept C2781161787 @default.
• W2892754564 hasConcept C55493867 @default.
• W2892754564 hasConcept C86803240 @default.
• W2892754564 hasConcept C98274493 @default.
• W2892754564 hasConceptScore W2892754564C134018914 @default.
• W2892754564 hasConceptScore W2892754564C170493617 @default.
• W2892754564 hasConceptScore W2892754564C185592680 @default.
• W2892754564 hasConceptScore W2892754564C2776151105 @default.
• W2892754564 hasConceptScore W2892754564C2777209548 @default.
• W2892754564 hasConceptScore W2892754564C2777765862 @default.
• W2892754564 hasConceptScore W2892754564C2778004101 @default.
• W2892754564 hasConceptScore W2892754564C2778979269 @default.
• W2892754564 hasConceptScore W2892754564C2779177272 @default.
• W2892754564 hasConceptScore W2892754564C2779719074 @default.
• W2892754564 hasConceptScore W2892754564C2781161787 @default.
• W2892754564 hasConceptScore W2892754564C55493867 @default.
• W2892754564 hasConceptScore W2892754564C86803240 @default.
• W2892754564 hasConceptScore W2892754564C98274493 @default.
• W2892754564 hasFunder F4320308402 @default.

• next